TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).
OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching impact on public health, as it accounts for 15% of all new cancer cases in the US and the most cancer-related deaths among both men and women. In the year 2015, it is estimated that 221,200 individuals will be diagnosed and 158,040 individuals will die from the disease. Despite the many advances over the past few decades related to surgery, radiation therapy and chemotherapy, death rates attributable to lung cancer have remained relatively unchanged. Today, however, there is renewed optimism that these trends have started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among scientists and clinicians working in this area of cancer medicine. A major focus of recent lung cancer research has been the development — and subsequent approval — of a number of molecular-targeted agents and the identification of related biomarkers to help guide treatment selection for those individuals who harbor specific oncogenic alterations.
These video proceedings from a CME symposium held in conjunction with the 16th World Conference on Lung Cancer feature discussions with leading researchers regarding actual cases of patients with NSCLC and tumor driver mutations from the practices of general medical oncologists and related clinical research findings to address existing uncertainties and help keep clinicians up to date and informed on the targeted treatment of NSCLC.
LEARNING OBJECTIVES
- Discriminate among molecular determinants that may be used to refine NSCLC prognosis and/or predict therapeutic response to an individual treatment, and apply available clinical guidelines to appropriately select patients for biomarker assessment.
- Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the long-term management of EGFR mutation-positive NSCLC.
- Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors (TKIs), and identify investigational therapeutic opportunities to circumvent this process.
- Communicate the efficacy and safety of crizotinib, ceritinib and other emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK and ROS1 mutation testing.
- Consider available clinical data and investigator perspectives when caring for patients with EGFR- or ALK-positive NSCLC and brain metastases.
- Assess new oncogenic pathways mediating the growth of unique NSCLC tumor subsets, and recall emerging data with experimental agents exploiting these targets.
- Recognize the abilities and limitations of multiplex and next-generation sequencing platforms, and determine their clinical and/or research application for patients with NSCLC.
- Appreciate the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in NSCLC, and counsel appropriately selected patients about study participation.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
D Ross Camidge, MD, PhD
Director, Thoracic Oncology Clinical Program
Associate Director for Clinical Research
University of Colorado Cancer Center
Aurora, Colorado
Consulting Agreements: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Biodesix Inc, Genentech BioOncology, ImmunoGen Inc, Lilly, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.
Pasi A Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Scientific Director
Belfer Institute for Applied Cancer Science
Boston, Massachusetts
Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Clovis Oncology, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi; Research Funding: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP; Stock Ownership: Gatekeeper Pharmaceuticals Inc; Other: LabCorp.
Mark G Kris, MD
William and Joy Ruane Chair in Thoracic Oncology
Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Advisory Committee: Daiichi Sankyo Inc; Consulting Agreements: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology; Contracted Research: Pfizer Inc, Puma Biotechnology Inc; Other Remunerated Activities: Roche Laboratories Inc.
Tony SK Mok, MD
Professor, Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China
Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc.
CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Paul Fishkin, MD
Illinois CancerCare, PC
Peoria, Illinois
William Harwin, MD
Florida Cancer Specialists
Fort Myers, Florida
Elizabeth D Simmons, MD
Los Angeles, California
CONSULTING ONCOLOGISTS — Drs Fishkin, Harwin and Simmons have no real or apparent conflicts of interest to disclose.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Foundation Medicine, Genentech BioOncology and Novartis Pharmaceuticals Corporation.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: November 2015
Expiration date: November 2016